Chani Stossel

Chani Stossel

Auto-generated profile, based on publicly available information

Chani Stossel

Oncology Institute, Sheba Medical Center, Tel Hashomer, Israel

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2023 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
CSChani Stossel
Chani Stossel
MRMaria Raitses-Gurevich
Maria Raitses-Gurevich
DADikla Atias
Dikla Atias
TBTamar Beller
Tamar Beller
YGYulia Glick Gorman
Yulia Glick Gorman
TGTalia Golan
Talia Golan
Germline BRCA–associated pancreatic ductal adenocarcinoma (glBRCA PDAC) tumors are susceptible to platinum and PARP inhibition. The clinical outcomes of 125 patients with glBRCA PDAC were stratified based on the spectrum of response to platinum/PARP inhibition: (i) refractory [overall survival (OS) <6 months], (ii) durable response followed by acquired resistance (OS 36 months). Patient-derived xenografts (PDX) were generated from 25 patients with glBRCA PDAC at different clinical time points. Response to platinum/PARP inhibition in vivo and ex vivo culture (EVOC) correlated with clinical response. We deciphered the mechanisms of resistance in glBRCA PDAC and identified homologous recombination (HR) proficiency and secondary mutations restoring partial functionality as the most dominant resistant mechanism. Yet, a subset of HR-deficient (HRD) patients demonstrated clinical resistance. Their tumors displayed basal-like molecular subtype and were more aneuploid. Tumor mutational burden was high in HRD PDAC and significantly higher in tumors with secondary mutations. Anti–PD-1 attenuated tumor growth in a novel humanized glBRCA PDAC PDX model. This work demonstrates the utility of preclinical models, including EVOC, to predict the response of glBRCA PDAC to treatment, which has the potential to inform time-sensitive medical decisions. Significance: glBRCA PDAC has a favorable response to platinum/PARP inhibition. However, most patients develop resistance. Additional treatment options for this unique subpopulation are needed. We generated model systems in PDXs and an ex vivo system (EVOC) that faithfully recapitulate these specific clinical scenarios as a platform to investigate the mechanisms of resistance for further drug development. This article is highlighted in the In This Issue feature, p. 1749

27 March 2023 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
OGOmer Goldman
Omer Goldman
LALital N. Adler
Lital N. Adler
EHEmma Hajaj
Emma Hajaj
TCTommaso Croese
Tommaso Croese
NDNaama Darzi
Naama Darzi
AEAyelet Erez
Ayelet Erez
Multiple studies have identified metabolic changes within the tumor and its microenvironment during carcinogenesis. Yet, the mechanisms by which tumors affect the host metabolism are unclear. We find that systemic inflammation induced by cancer leads to liver infiltration of myeloid cells at early extrahepatic carcinogenesis. The infiltrating immune cells via IL6–pSTAT3 immune–hepatocyte cross-talk cause the depletion of a master metabolic regulator, HNF4α, consequently leading to systemic metabolic changes that promote breast and pancreatic cancer proliferation and a worse outcome. Preserving HNF4α levels maintains liver metabolism and restricts carcinogenesis. Standard liver biochemical tests can identify early metabolic changes and predict patients’ outcomes and weight loss. Thus, the tumor induces early metabolic changes in its macroenvironment with diagnostic and potentially therapeutic implications for the host. Significance: Cancer growth requires a permanent nutrient supply starting from early disease stages. We find that the tumor extends its effect to the host's liver to obtain nutrients and rewires the systemic and tissue-specific metabolism early during carcinogenesis. Preserving liver metabolism restricts tumor growth and improves cancer outcomes. This article is highlighted in the In This Issue feature, p. 1501


11 December 2025
Verified
Other
Open access
OGOmer Goldman
Omer Goldman
LALital N. Adler
Lital N. Adler
EHEmma Hajaj
Emma Hajaj
TCTommaso Croese
Tommaso Croese
NDNaama Darzi
Naama Darzi
AEAyelet Erez
Ayelet Erez
Supplementary Table S3 lists the primers used for qPCR

11 December 2025
Verified
Other
Open access
OGOmer Goldman
Omer Goldman
LALital N. Adler
Lital N. Adler
EHEmma Hajaj
Emma Hajaj
TCTommaso Croese
Tommaso Croese
NDNaama Darzi
Naama Darzi
AEAyelet Erez
Ayelet Erez
Supplementary Figure S4 demonstrates similar transcriptional and metabolic changes following liver infiltration of immune cells to the liver of PDAC mice

11 December 2025
Verified
Other
Open access
OGOmer Goldman
Omer Goldman
LALital N. Adler
Lital N. Adler
EHEmma Hajaj
Emma Hajaj
TCTommaso Croese
Tommaso Croese
NDNaama Darzi
Naama Darzi
AEAyelet Erez
Ayelet Erez
Supplementary Extended Data 1 describes the FACS gating startegy